Chao Liu, Zheng Pengyuan, Xia Liu, Yong Yu, Lu Gaofeng, Tang Fuai, Zhao Zhiguo
Department of Gastroenterology, the Affiliated Second Hospital of Zhengzhou University, Zhengzhou, 450014, China.
Department of Gastroenterology, the Affiliated Fifth Hospital of Zhengzhou University, Zhengzhou, 450014, China.
Iran J Basic Med Sci. 2017 Sep;20(9):1056-1062. doi: 10.22038/IJBMS.2017.9276.
Inflammatory bowel disease (IBD) results from dysregulation of intestinal mucosal immunity. It is an incurable disease that affects millions of people worldwide. Developing new strategies for the treatment of colitis has been a major challenge. Here, we report the effect of calycosin, a plant-derived flavonoid, in successfully managing colitis in murine model.
model of colitis was induced using 2.5% (w/v) dextran sodium sulfate (DSS, 36,000 to 50,000 Mw). Body weight and disease activity index (DAI) were evaluated every day. Hematoxylin-Eosin (H&E) staining was used to estimate the effect of calycosin on DSS-induced colon damage. The levels of proinflammatory genes and mRNA expression were determined using real-time PCR, whereas the proinflammatory cytokines were assessed with ELISA. The content of other parameters including myeloperoxidase (MPO), glutathione (GSH), superoxide dismutase (SOD) and malondialdehyde (MDA) were also evaluated. Western blot assay was further used to determine the effect of calycosin on both NF-κB and mitogen activated protein kinases (MAPK) pathways.
The results showed that calycosin prevented weight loss and shortening of the colon length, maintained an intact mucosa, increased GSH and SOD activities, and decreased MDA levels. The drug also significantly inhibited proinflammatory cytokine mRNA expression and decreased MPO activity. Additionally, it remarkably inhibited NF-κB pathway and c-Jun N-terminal kinase (JNK) phosphorylation with no effect on p38 and extracellular signal-regulated kinase (ERK1/2) phosphorylation levels in colon tissue.
These findings revealed that calycosin successfully ameliorated the effect of DSS-induced colitis in mice, which could be associated with NF-κB and JNK pathway modulations.
炎症性肠病(IBD)是由肠道黏膜免疫失调引起的。它是一种无法治愈的疾病,影响着全球数百万人。开发治疗结肠炎的新策略一直是一项重大挑战。在此,我们报告了毛蕊异黄酮(一种植物来源的黄酮类化合物)在成功治疗小鼠结肠炎模型中的作用。
使用2.5%(w/v)葡聚糖硫酸钠(DSS,分子量36,000至50,000)诱导结肠炎模型。每天评估体重和疾病活动指数(DAI)。苏木精-伊红(H&E)染色用于评估毛蕊异黄酮对DSS诱导的结肠损伤的影响。使用实时PCR测定促炎基因和mRNA表达水平,而用ELISA评估促炎细胞因子。还评估了包括髓过氧化物酶(MPO)、谷胱甘肽(GSH)、超氧化物歧化酶(SOD)和丙二醛(MDA)在内的其他参数的含量。进一步使用蛋白质印迹分析来确定毛蕊异黄酮对NF-κB和丝裂原活化蛋白激酶(MAPK)途径的影响。
结果表明,毛蕊异黄酮可防止体重减轻和结肠长度缩短,维持黏膜完整,增加GSH和SOD活性,并降低MDA水平。该药物还显著抑制促炎细胞因子mRNA表达并降低MPO活性。此外,它显著抑制NF-κB途径和c-Jun氨基末端激酶(JNK)磷酸化,对结肠组织中p38和细胞外信号调节激酶(ERK1/2)磷酸化水平无影响。
这些发现表明,毛蕊异黄酮成功改善了DSS诱导的小鼠结肠炎的影响,这可能与NF-κB和JNK途径调节有关。